PortfoliosLab logoPortfoliosLab logo
ISIN
US37733W1053
CUSIP
37733W105
IPO Date
Jul 9, 1986

Highlights

Market Cap
$103.20B
Enterprise Value
$129.24B
EPS (TTM)
£2.36
PE Ratio
16.16
PEG Ratio
0.36
Total Revenue (TTM)
£33.25B
Gross Profit (TTM)
£24.35B
EBITDA (TTM)
£10.68B
Year Range
$36.75 - $61.70
Target Price
$52.45
ROA (TTM)
7.86%
ROE (TTM)
27.50%
Avg. Volume (1M)
5M
Avg. Volume Value (1M)
$239.22M

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

GSK Performance Chart

GSK plc (GSK) is up 6.9% since the beginning of the year. At $52 per share, GSK is trading 16.5% below its 52-week high of $62. Investors who bought $1,000 worth of GSK shares 5 years ago would now be looking at an investment worth $1,250.


Loading charts...

Benchmark

Compare this symbol against anything

Returns By Period

GSK plc (GSK) has returned 6.85% so far this year and 42.28% over the past 12 months. Over the last ten years, GSK has returned 3.87% per year, falling short of the S&P 500 Index benchmark, which averaged 13.29% annually.


GSK plc

1D
-0.35%
1M
-4.01%
6M
-0.14%
YTD
6.85%
1Y
42.28%
3Y*
19.02%
5Y*
4.56%
10Y*
3.87%
ALL TIME*
8.46%

Benchmark (S&P 500 Index)

1D
1.48%
1M
1.57%
6M
8.95%
YTD
11.03%
1Y
21.84%
3Y*
19.28%
5Y*
11.54%
10Y*
13.29%
ALL TIME*
8.11%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GSK Monthly Returns History

Based on dividend-adjusted daily data since Jul 9, 1986, GSK's average daily return is +0.05%, while the average monthly return is +0.88%. At this rate, an investment would double in approximately 6.6 years.

Historically, 57% of months were positive and 43% were negative. The best month was Jan 1987 with a return of +27.6%, while the worst month was Oct 1987 at -31.6%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 7 months.

On a daily basis, GSK closed higher 49% of trading days. The best single day was Feb 2, 1998 with a return of +16.6%, while the worst single day was Oct 19, 1987 at -22.0%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20265.22%15.51%-6.66%-5.22%-2.50%3.72%-1.39%-0.35%6.85%
20254.29%7.75%3.06%2.87%4.15%-6.41%-3.26%7.96%8.80%8.57%3.03%2.47%51.23%
20246.42%7.28%2.32%-3.34%8.93%-14.00%0.70%14.32%-6.90%-10.08%-6.09%-0.91%-5.14%
20230.34%-1.87%3.82%1.26%-5.84%6.07%-0.20%-0.21%3.19%-1.52%1.82%2.97%9.71%
20221.63%-5.24%4.06%3.95%-2.26%-0.84%-22.50%-22.10%-9.39%12.71%5.30%1.59%-33.41%
20211.22%-8.17%6.19%4.62%5.24%2.71%0.80%2.79%-6.21%10.78%-1.66%7.25%26.74%

Benchmark Metrics

GSK plc has an annualized alpha of 4.67%, beta of 0.69, and R2 of 0.23 versus S&P 500 Index. Calculated based on daily prices since July 09, 1986.

  • This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (61.76%) than losses (56.91%) - typical of diversified or defensive assets.
  • Beta of 0.69 may look defensive, but with R2 of 0.23 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.23 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
4.67%
Beta
0.69
0.23
Upside Capture
61.76%
Downside Capture
56.91%

Return for Risk

Risk / Return Rank

GSK ranks 83 for risk / return — above 83% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.


GSK Risk / Return Rank: 8383
Overall Rank
GSK Sharpe Ratio Rank: 8686
Sharpe Ratio Rank
GSK Sortino Ratio Rank: 8585
Sortino Ratio Rank
GSK Omega Ratio Rank: 8282
Omega Ratio Rank
GSK Calmar Ratio Rank: 8181
Calmar Ratio Rank
GSK Martin Ratio Rank: 7979
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

Risk / Return Metrics

The table below present risk-adjusted performance metrics for GSK plc (GSK) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GSKBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-0.11

Sortino ratioReturn per unit of downside risk

0.00

Omega ratioGain probability vs. loss probability

1.28

1.31

-0.02

Calmar ratioReturn relative to maximum drawdown

2.29

2.41

-0.12

Martin ratioReturn relative to average drawdown

4.96

10.22

-5.26

Dividends

Dividend History

GSK plc provided a 3.48% dividend yield over the last twelve months, with an annual payout of $1.79 per share. The company has been increasing its dividends for 2 consecutive years.


3.00%4.00%5.00%6.00%7.00%$0.00$0.50$1.00$1.50$2.00$2.50$3.00$3.5020152016201720182019202020212022202320242025
Dividends
Dividend Yield
PeriodTTM20252024202320222021202020192018201720162015
Dividend$1.79$1.67$1.56$1.39$1.92$2.75$2.57$2.56$2.70$2.58$3.30$2.99

Dividend yield

3.48%3.42%4.60%3.75%5.47%4.99%5.59%4.35%5.65%5.83%6.86%5.93%

Monthly Dividends

The table displays the monthly dividend distributions for GSK plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.49$0.00$0.00$0.46$0.00$0.00$0.00$0.95
2025$0.00$0.40$0.00$0.00$0.43$0.00$0.00$0.43$0.00$0.00$0.42$0.00$1.67
2024$0.00$0.41$0.00$0.00$0.38$0.00$0.00$0.39$0.00$0.00$0.39$0.00$1.56
2023$0.00$0.34$0.00$0.00$0.35$0.00$0.00$0.36$0.00$0.00$0.34$0.00$1.39
2022$0.00$0.78$0.00$0.00$0.44$0.00$0.00$0.39$0.00$0.00$0.32$0.00$1.92
2021$0.00$0.79$0.00$0.00$0.66$0.00$0.00$0.66$0.00$0.00$0.65$0.00$2.75

Dividend Yield & Payout


Dividend Yield

GSK plc has a dividend yield of 3.48%, which is quite average when compared to the overall market.

Payout Ratio

GSK plc has a payout ratio of 60.24%, which is quite average when compared to the overall market. This suggests that GSK plc strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the GSK plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the GSK plc was 55.70%, occurring on Aug 13, 1993. Recovery took 769 trading sessions.

The current GSK plc drawdown is 14.35%.


Drawdown

Fall

Recovery

Underwater

Related event

-55.70%Aug 1993
1y 7mo3y 16d
4y 7moJan 1992 - Aug 1996
-51.64%Jul 2002
3y 6mo4y 6mo
8y 1moJan 1999 - Feb 2007
Dot-com crash2000–2002
-50.10%Sep 2022
5mo 16d3y 3mo
3y 8moApr 2022 - Jan 2026
Bear market2022
-49.62%Mar 2009
1y 10mo3y 1mo
4y 12moApr 2007 - Apr 2012
Financial crisis2007–2009
-45.98%Aug 1988
1y 1mo1y 8mo
2y 9moJul 1987 - May 1990

Drawdown Indicators


GSKBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-55.70%

-56.78%

+1.08%

Max Drawdown (1Y)

Largest decline over 1 year

-18.53%

-9.10%

-9.43%

Max Drawdown (3Y)

Largest decline over 3 years

-28.46%

-18.90%

-9.56%

Max Drawdown (5Y)

Largest decline over 5 years

-50.10%

-25.43%

-24.67%

Max Drawdown (10Y)

Largest decline over 10 years

-50.10%

-33.92%

-16.18%

Current Drawdown

Current decline from peak

-14.35%

-0.12%

-14.23%

Average Drawdown

Average peak-to-trough decline

-18.85%

-10.70%

-8.15%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.54%

2.14%

+6.40%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of GSK plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how GSK plc is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for GSK, comparing it with other companies in the Drug Manufacturers - General industry. Currently, GSK has a P/E ratio of 16.2. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for GSK compared to other companies in the Drug Manufacturers - General industry. GSK currently has a PEG ratio of 0.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for GSK relative to other companies in the Drug Manufacturers - General industry. Currently, GSK has a P/S ratio of 2.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for GSK in comparison with other companies in the Drug Manufacturers - General industry. Currently, GSK has a P/B value of 4.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with GSK

Add GSK plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with GSK